HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Factitious blistering — Clinical Guidelines

Overview

Factitious blistering encompasses a range of autoimmune blistering diseases characterized by the formation of blisters due to autoantibodies targeting structural proteins in the skin and mucous membranes, leading to significant morbidity and potential mortality 1 2 4 5 10 11.

Diagnosis

Clinical Presentation: Presence of characteristic blistering patterns (subepidermal, intraepidermal) 1 10.

Histopathology: Examination of skin biopsies to identify characteristic changes 2 3.

Immunopathology: Direct immunofluorescence (DIF) and indirect immunofluorescence (IIF) tests to detect autoantibodies 3 11.

Severity Scoring: Use of validated indexes like ABSIS and PDAI for disease severity assessment 9.

Management

First-Line Treatments:

- Corticosteroids: Topical (class IV) and systemic (prednisolone 0.5-1.0 mg/kg/d) 4 5 15. - Immunosuppressants: Azathioprine, dapsone, and other agents like methotrexate or mycophenolate mofetil 4 5 15.

Adjunctive Treatments:

- Immunoadsorption (IA): Effective for severe or refractory cases 11 17. - Intravenous Immunoglobulin (IVIG): Used in specific immune-mediated skin diseases, guided by consensus statements 18.

Special Populations

Pediatrics: Unique considerations in diagnosis and management due to developmental differences 10.

Pregnancy: Specific autoimmune blistering diseases like pemphigoid gestationis require tailored management 4.

Elderly: Increased risk of comorbidities affecting treatment choices and outcomes 15.

Comorbidities: Careful consideration of concomitant conditions influencing treatment efficacy and safety 7.

Key Recommendations

Use validated severity scoring systems (ABSIS, PDAI) for monitoring disease progression and treatment response (Evidence: Moderate 9).

Initiate treatment with systemic corticosteroids combined with immunosuppressants like azathioprine or dapsone (Evidence: Moderate 4 5 15).

Consider immunoadsorption as an adjunctive therapy for refractory cases (Evidence: Weak 11 17).

Tailor management strategies considering patient-specific factors such as age and comorbidities (Evidence: Expert opinion 7 15).

Participate in multicenter studies and registries for better epidemiological understanding and improved patient care (Evidence: Expert opinion 12 13).

References

1 Chernyshov PV, Finlay AY, Patsatsi A, Marinović B, Salavastru C, Murrell DF et al.. Quality of Life Measurement in Autoimmune Blistering Diseases: Mutual Position Statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Autoimmune Blistering Diseases. International journal of dermatology 2026. link 2 Huang S, Anderson HJ, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part II. Diagnosis and management. Journal of the American Academy of Dermatology 2024. link 3 Cocks MM. A Starter Guide to Immunofluorescence Testing in Dermatology. Cutis 2021. link 4 Patel PM, Jones VA, Murray TN, Amber KT. A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita. American journal of clinical dermatology 2020. link 5 Santi CG, Gripp AC, Roselino AM, Mello DS, Gordilho JO, Marsillac PF et al.. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology. Anais brasileiros de dermatologia 2019. link 6 Hussain A, Sanders M, Riotte C, Hussain N. Full-term newborn infant with blistering skin lesions-Caution regarding use of pain medications. Pediatric dermatology 2019. link 7 Ehsani-Chimeh N, Marinkovich MP. Practice and Educational Gaps in Blistering Disease. Dermatologic clinics 2016. link 8 Rosenau J. Science denial: a guide for scientists. Trends in microbiology 2012. link 9 Daniel BS, Hertl M, Werth VP, Eming R, Murrell DF. Severity score indexes for blistering diseases. Clinics in dermatology 2012. link 10 Sansaricq F, Stein SL, Petronic-Rosic V. Autoimmune bullous diseases in childhood. Clinics in dermatology 2012. link 11 Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2012. link 12 Marinovic B, Lipozencic J, Jukic IL. Autoimmune blistering diseases: incidence and treatment in Croatia. Dermatologic clinics 2011. link 13 Daniel BS, Dermawan A, Murrell DF. The autoimmune blistering diseases in Australia: status and services. Dermatologic clinics 2011. link 14 Suárez R, España A, Herrero-González JE, Iranzo P, Mascaró JM. Management of autoimmune blistering diseases in Spain. Dermatologic clinics 2011. link 15 Schmidt E, Zillikens D. Diagnosis and treatment of patients with autoimmune bullous disorders in Germany. Dermatologic clinics 2011. link 16 Nagy N, McGrath JA. Blistering skin diseases: a bridge between dermatopathology and molecular biology. Histopathology 2010. link 17 Schmidt E, Zillikens D. Immunoadsorption in dermatology. Archives of dermatological research 2010. link 18 Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. Journal of cutaneous medicine and surgery 2006. link

Factitious blistering